Premium
Can Fite BioPharma Ltd (CANF)
AMEX
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III t... Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.2 | -11.2359550562 | 1.78 | 1.81 | 1.52 | 70350 | 1.64370787 | CS |
| 4 | 0.15 | 10.4895104895 | 1.43 | 2.04 | 1.37 | 115844 | 1.69986856 | CS |
| 12 | 0.03 | 1.93548387097 | 1.55 | 2.04 | 1.3 | 125034 | 1.58584267 | CS |
| 26 | -0.69 | -30.3964757709 | 2.27 | 3.12 | 1.29 | 276587 | 1.70631033 | CS |
| 52 | -0.62 | -28.1818181818 | 2.2 | 4.69 | 1.29 | 171494 | 1.96084586 | CS |
| 156 | -8.72 | -84.6601941748 | 10.3 | 12.9 | 1.29 | 136294 | 5.28913775 | CS |
| 260 | -13.62 | -89.6052631579 | 15.2 | 43.9 | 1.29 | 669455 | 20.20574407 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
